3,6-Dioxa-octanedithioamide | 864943-29-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 英文名称: 3,6-Dioxa-octanedithioamide
• 英文别名: 2-[2-(2-amino-2-sulfanylideneethoxy)ethoxy]ethanethioamide
• CAS: 864943-29-3
• 化学式: C₆H₁₂N₂O₂S₂
• 分子量: 208.3
• InChiKey: REARNVCGKBEYLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Ion-detecting microspheres and methods of use thereof
  申请人：Auburn University

  公开号：US20040058384A1

  公开（公告）日：2004-03-25

  This invention provides methods of using ion-detecting microspheres containing an ionphore and a chromoionphore in clinical laboratory instrumentation such as flow cytometry for sample analysis. In one embodiment, the microspheres are contacted with a flowing stream of a sample under conditions that allow the ion-selective ionophores to complex with the ions in the sample, and to cause deprotonation of the chromoionophore. The complexes are then exposed to an excitation wavelength light source suitable for exciting the deprotonated chromoionophore to emit a fluorescence signal pattern. Detection of the fluorescence signal pattern emitted by the deprotonated chromoionophore in microspheres containing the complexes allows for determination of the presence of the target ions in the sample. In one embodiment, lead ion-detecting microspheres are provided that can detect nanomolar levels of lead ions with response times on the order of minutes.

  本发明提供了在临床实验室仪器（如流式细胞仪）中使用含有离子亲体和发色团的离子检测微球进行样品分析的方法。在一个实施方案中，将微球与流动的样品流接触，使离子选择性亲离子与样品中的离子复合，并引起亲色团的去质子化。然后将复合物暴露在适合激发去质子化的发色团的激发波长光源下，使其发出荧光信号图案。通过检测含有络合物的微球中去质子化的发色团发出的荧光信号图案，可以确定样品中是否存在目标离子。在一个实施方案中，提供的铅离子检测微球可检测纳摩尔级的铅离子，响应时间约为几分钟。
• Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals
  申请人：Takemoto C. Arnold

  公开号：US20050208118A1

  公开（公告）日：2005-09-22

  This invention provides, in non-limiting embodiments, novel preparations of chelating agents encapsulated in micelles or liposomes comprising the triple combination of: 1) micelles or liposomes comprising alpha lipoic acid or a derivative thereof and 2) micelles or liposomes comprising a chelating agent, such as EDTA; and furthermore, in different embodiments, optionally 3) magnesium chloride. The micelles or liposomes may be comprised of what have been termed “essential phospholipids”.

  本发明在非限制性实施例中提供了包封在胶束或脂质体中的螯合剂的新型制剂，该制剂包括以下三重组合：1）包含α-硫辛酸或其衍生物的胶束或脂质体；2）包含螯合剂（如 EDTA）的胶束或脂质体；此外，在不同的实施方案中，还可选择 3）氯化镁。胶束或脂质体可由所谓的 "必需磷脂 "组成。
• Encapsulated oral chelating preparations
  申请人：Takemoto C. Arnold

  公开号：US20050208119A1

  公开（公告）日：2005-09-22

  This invention provides, in non-limiting embodiments, novel preparations of chelating agents encapsulated in micelles or liposomes comprising the triple combination of: 1) micelles or liposomes comprising alpha lipoic acid or a derivative thereof and 2) micelles or liposomes comprising a chelating agent, such as EDTA; and furthermore, in different embodiments, optionally 3) magnesium chloride. The micelles or liposomes may be comprised of what have been termed “essential phospholipids”.

  本发明在非限制性实施例中提供了包封在胶束或脂质体中的螯合剂的新型制剂，该制剂包括以下三重组合：1）包含α-硫辛酸或其衍生物的胶束或脂质体；2）包含螯合剂（如 EDTA）的胶束或脂质体；此外，在不同的实施方案中，还可选择 3）氯化镁。胶束或脂质体可由所谓的 "必需磷脂 "组成。
• Breast health preparations
  申请人：Takemoto C. Arnold

  公开号：US20050209170A1

  公开（公告）日：2005-09-22

  Novel preparations of phytochemical ingredients that are serviceable as health supplements for the body, particularly tissues susceptible to cancer, including, e.g. prostate tissue and breast tissue and, including, e.g., female breast tissue; for example, all possible combinations and permutations of member from each of the following 5 groups: 1) plant indoles, including sources of plant indoles (e.g. diindolemethane); 2) plant flavonoids, polyphenols, stilbenes and related substances, including sources of plant flavonoids, polyphenols, stilbenes, and related substances (e.g. resveratrol and piceatannol); 3) D-glucaric acid and derivatives thereof (e.g. calcium D-glucarate and 1,4-GL) and sources thereof; 4) medium chain triglycerides and sources thereof; and 5) phospholipids and sources thereof (e.g. lecithin).

  可作为人体保健品的植物化学成分的新制剂，特别是易患癌症的组织，包括如前列腺组织和乳腺组织，以及包括如女性乳腺组织、1) 植物吲哚，包括植物吲哚的来源（如二吲哚甲烷）； 2) 植物黄酮类、多酚类、二苯乙烯类及相关物质，包括植物黄酮类、多酚类、二苯乙烯类及相关物质的来源（如白藜芦醇和对羟基苯甲酸酯）； 3) 植物雌激素，包括植物雌激素的来源（如白藜芦醇和对羟基苯甲酸酯）。3) D-葡萄糖酸及其衍生物（如 D-葡萄糖酸钙和 1,4-GL）及其来源； 4) 中链甘油三酯及其来源；以及 5) 磷脂及其来源（如卵磷脂）。
• Detoxification and breast health preparations
  申请人：Takemoto C. Arnold

  公开号：US20050209551A1

  公开（公告）日：2005-09-22

  Novel preparations of phytochemical ingredients that are serviceable as health supplements for the body, particularly tissues susceptible to cancer, including, e.g. prostate tissue and breast tissue and, including, e.g., female breast tissue; for example, all possible combinations and permutations of member from each of the following 5 groups: 1) plant indoles, including sources of plant indoles (e.g. diindolemethane); 2) plant flavonoids, polyphenols, stilbenes and related substances, including sources of plant flavonoids, polyphenols, stilbenes, and related substances (e.g. resveratrol and piceatannol); 3) D-glucaric acid and derivatives thereof (e.g. calcium D-glucarate and 1,4-GL) and sources thereof; 4) medium chain triglycerides and sources thereof; and 5) phospholipids and sources thereof (e.g. lecithin).

  可作为人体保健品的植物化学成分的新制剂，特别是易患癌症的组织，包括如前列腺组织和乳腺组织，以及包括如女性乳腺组织、1) 植物吲哚，包括植物吲哚的来源（如二吲哚甲烷）； 2) 植物黄酮类、多酚类、二苯乙烯类及相关物质，包括植物黄酮类、多酚类、二苯乙烯类及相关物质的来源（如白藜芦醇和对羟基苯甲酸酯）； 3) 植物雌激素，包括植物雌激素的来源（如白藜芦醇和对羟基苯甲酸酯）。3) D-葡萄糖酸及其衍生物（如 D-葡萄糖酸钙和 1,4-GL）及其来源； 4) 中链甘油三酯及其来源；以及 5) 磷脂及其来源（如卵磷脂）。